Three partners committed to combat AMR
Evotec, Boehringer Ingelheim, and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
07-Jul-2022 -
Evotec SE, Boehringer Ingelheim and bioMérieux announced that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR).
The resulting company, Aurobac Therapeutics SAS, will combine the best-of-best ...
antibiotic resistance
antimicrobial resistance
antimicrobials
+5